GOG-3107 RAINFOL Rinatabart versus Investigator's Choice (Ovarian Cancer)

If you choose to join this study, you will go through a screening period to make sure you are eligible. During this period, you will:

• Have a tumor biopsy
• Have a physical exam
• Have blood draws and give urine samples
• Have heart scans (echocardiogram and EKG)
• Have imaging done (CT and/or MRI)

If you are eligible based on screening, you will proceed to the study dosing period. During this period, you will get a random assignment (50:50 chance, like a coin flip) to either get the study drug or get treatment with a standard chemotherapy regimen. If you are assigned to take the study drug, you will get the study drug as an intravenous (IV) infusion once every 3 weeks. If you are assigned to get a standard chemotherapy treatment, the study doctor will decide what available treatment is most appropriate for you. The study doctor will choose from 4 options:

• Paclitaxel, given as an IV infusion on Days 1, 8, and 15 every 4 weeks
• Topotecan, given as an IV infusion on Days 1, 8 and 15 every 4 weeks, or as an IV infusion on Days 1-5 every 3 weeks (the study doctor will decide on the dosing schedule)
• Pegylated liposomal doxorubicin, given as an IV infusion once every 4 weeks
• Gemcitabine, given as an IV infusion on Days 1, 8, and 15 every 4 weeks

You will take your assigned study regimen for as long as the study doctor believes that you are getting a benefit. After you stop your regimen, we will schedule you to come in for follow-up visits to see how you are doing.